Celivarone

CAS No. 401925-43-7

Celivarone( —— )

Catalog No. M36144 CAS No. 401925-43-7

Celivarone is a potassium channel blocker used in the study of arrhythmias, atrial flutter and atrial fibrillation.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 290 Get Quote
5MG 447 Get Quote
10MG 655 Get Quote
25MG 994 Get Quote
50MG 1343 Get Quote
100MG 1764 Get Quote
500MG 3537 Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    Celivarone
  • Note
    Research use only, not for human use.
  • Brief Description
    Celivarone is a potassium channel blocker used in the study of arrhythmias, atrial flutter and atrial fibrillation.
  • Description
    Celivarone is a potassium channel blocker used in the study of arrhythmias, atrial flutter and atrial fibrillation.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Cell Cycle/DNA Damage
  • Target
    Potassium Channel
  • Recptor
    Potassium Channel
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    401925-43-7
  • Formula Weight
    533.74
  • Molecular Formula
    C34H47NO4
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    C(=O)(C=1C=2C(OC1CCCC)=CC=C(C(OC(C)C)=O)C2)C3=CC=C(CCCN(CCCC)CCCC)C=C3
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

molnova catalog
related products
  • Azimilide

    A class ΙΙΙ antiarrhythmic agent that blocks hERG channel; blocks HERG channel at 0.1 and 1 Hz with IC50s of 1.4 uM and 5.2 uM respectively.

  • Senicapoc

    A potent, selective Gardos channel blocker that blocks Ca(2+)-induced rubidium flux from human RBCs (IC50=11 nM) and inhibits RBC dehydration (IC50=10-50 nM).

  • XE 991 dihydrochlori...

    A potent, selective and orally active blocker of voltage-gated potassium channels Kv7 (KCNQ) that blocks KCNQ1, KCNQ2 and KCNQ2+KCNQ3 with Kd of 0.78, 0.7 and 0.6 uM, respectively.